Kewaunee Scientific (NASDAQ:KEQU) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of Kewaunee Scientific (NASDAQ:KEQU) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

Kewaunee Scientific Stock Performance

NASDAQ KEQU opened at $47.58 on Friday. Kewaunee Scientific has a 1 year low of $30.74 and a 1 year high of $71.33. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13. The firm has a market cap of $136.65 million, a price-to-earnings ratio of 7.54 and a beta of 0.71. The company has a fifty day moving average price of $58.59 and a 200-day moving average price of $47.92.

Kewaunee Scientific (NASDAQ:KEQU) last posted its earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. Kewaunee Scientific had a net margin of 9.39% and a return on equity of 25.83%. The firm had revenue of $67.17 million during the quarter.

Insider Activity at Kewaunee Scientific

In related news, CEO Thomas David Hull III sold 1,368 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $60.08, for a total transaction of $82,189.44. Following the completion of the transaction, the chief executive officer now owns 41,129 shares in the company, valued at approximately $2,471,030.32. This represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Donald T. Gardner III sold 2,049 shares of the stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $58.19, for a total transaction of $119,231.31. Following the transaction, the chief financial officer now owns 22,615 shares of the company’s stock, valued at approximately $1,315,966.85. The trade was a 8.31 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,994 shares of company stock worth $729,430. 14.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kewaunee Scientific

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in Kewaunee Scientific by 2,605.9% during the fourth quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock valued at $28,000 after purchasing an additional 443 shares during the last quarter. IFP Advisors Inc purchased a new stake in Kewaunee Scientific during the fourth quarter valued at about $36,000. O Shaughnessy Asset Management LLC lifted its holdings in Kewaunee Scientific by 3.3% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 28,008 shares of the technology company’s stock valued at $1,733,000 after purchasing an additional 891 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock valued at $30,000 after purchasing an additional 900 shares during the last quarter. Finally, Ritholtz Wealth Management lifted its holdings in Kewaunee Scientific by 15.6% during the fourth quarter. Ritholtz Wealth Management now owns 12,619 shares of the technology company’s stock valued at $781,000 after purchasing an additional 1,706 shares during the last quarter. Institutional investors own 32.69% of the company’s stock.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.